Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Staff exchange2019–2024

INNOVA4TB · Innovation in Tuberculosis

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2019-01-01 → 2024-06-30
EU contribution
€1,039,600
Participants
16
Scheme
MSCA-RISE

Lines connect the coordinator with its partners.

Results in brief

Innovation in Tuberculosis

The incidence of tuberculosis (TB) is still high in several countries, and it is one of the major infectious diseases worldwide. The emergence and spread of multi-drug and extensive resistant cases is a public health threat. In addition, the armed conflicts that is experiencing Europe, and other part of the world, have provoked a large number of refugees and displaced population. However, the conventional methods used for diagnosis and drug-susceptibility testing are not enough for controlling the disease. In addition, all TB patients, independently of their age, gender, severity of the disease and type of responsible strain, follow the same treatment duration, which often leads to high frequency of adverse events, suboptimal adherence to treatment, and poor outcome. A progressive transition from programmatic to personalized management of TB is needed. Our proposal has developed innovative technologies and approaches in order to improve the individual risk assessment for TB development if the patient is infected; to rapidly diagnose active TB using new methods applied to non-sputum samples; to detect the drug susceptibility of the strain using molecular methods; to design tailor-made therapies including the exploration of new molecules and new ways of delivery; and to use blood and X-ray biomarkers to guide and individualize the duration of antimicrobial therapy. All these achievements are of great importance for improving the quality of life of patients and ensuring treatment success, as well as for economic reasons for the healthcare system. The overall objective of INNOVA4TB was to enhance and strengthen the collaborative research among sectors and to form a network aimed to perform high-quality and translational research in the field of diagnosis and management of TB. The consortium is constituted by 16 institutions from 8 countries that combined complementary and synergic expertise: clinical management (hospitals), basic science and new technologies (academic institutions), and industrial development and entrepreneurship culture (SMEs). The exchanges between the institutions have allowed the participants to progress in their career perspectives.

Data: CORDIS, © European Union

Project objective

The objective of INNOVA4TB is to enhance and strengthen the collaborative research among sectors and to form a network aimed to perform high-quality and translational research in the field of diagnosis and management of tuberculosis (TB). The consortium is constituted by 12 institutions from 8 countries that combine complementary and synergic expertise: clinical management (hospitals), basic science and new technologies (academic institutions), and industrial development and entrepreneurship culture (SMEs). The exchanges between the institutions allow the participants to progress in their career perspectives.TB is one of the major infectious diseases worldwide, and the emergence and spread of drug resistant cases is a public health threat. However, the conventional methods used for diagnosis and drug-susceptibility testing are not enough for controlling the disease. In addition, all TB patients, independently of their age, gender, severity of the disease and type of responsible strain, follow the same treatment duration (up to 20 months in drug resistant cases), which often leads to high frequency of adverse events, suboptimal adherence to treatment, and poor outcome. A transition from programmatic to personalized management of TB is needed. Our proposal will develop innovative technologies and approaches in order to improve the individual risk assessment for TB development, to rapidly diagnose active TB, to detect the drug susceptibility of the strain, to design tailor-made therapies, and to use biomarkers to guide and individualize the duration of antimicrobial therapy. This is of great importance for improving the quality of life of patients and ensuring treatment success, as well as for economic reasons for the healthcare system.

Original text from CORDIS.

Participants

  • INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL · Badalona BarcelonaCoordinatorSpain
  • ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE · San SebastianSpain
  • CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. · MadridSpain
  • EMPE DIAGNOSTICS AB · StockholmSweden
  • Genome Identification Diagnostics GmbH · StrassbergGermany
  • INSTITUTIA MEDICO-SANITARA PUBLICA - INSTITUTUL DE PNEUMOLOGIE ""CHIRIL DRAGANIUC"""" · CHISINAUMoldova
  • INSTITUTO ARAGONES DE CIENCIAS DE LA SALUD · ZARAGOZASpain
  • KOMUNALNE NEKOMERSHCHYNE PRIDPRYEMSTVO ODESKYY OBLASNYY TSENTR SOTSIALNO ZNACHUCHYKH KHVOROB ODESKOI OBLASNOY RADY · OdesaUkraine
  • MAGRITEK GMBH · AachenGermany
  • ODESKIY NACIONALNIY UNIVERSITET IMENI I.I. MECHNIKOVA · OdessaUkraine
  • SERVICIOS CLINICOS SA · BarcelonaSpain
  • UMEA UNIVERSITET · UMEASweden
  • UNIVERSIDAD DE LA FRONTERA · TemucoChile
  • UNIVERSIDAD DE ZARAGOZA · ZaragozaSpain
  • UNIVERSIDAD POLITECNICA DE MADRID · MadridSpain
  • VINNYTSIA NATIONAL M.I. PYROGOV MEDICAL UNIVERSITY · VinnitsaUkraine

Links

Data: CORDIS, © European Union